Introduction
The only definitive treatment for severe hepatic failure is orthotopic transplantation. However, a critical shortage of organs is causing an increasing deficit of organs, cur rently around 4,000 livers per year. 1 Tissue engineering has the potential to cover the donor organ gap via the creation of arti ficial tissues. However, despite decades attempting to create tissues by fabricating scaffolds, beginning with microarchitecture at the cellular level and using synthetic bio materials, tissueengineered organs have not yet been successfully introduced into a clinical setting. 2, 3 The commercial success of regenerative medicine has mainly been restricted to noncellular products; examples are acellular skin matrix components and cartilage replacements. 3 This Perspectives article describes the current status of the field of livertissue engineering and outlines some of the chal lenges being encountered. Some of the novel solutions being developed to over come those challenges are discussed; hope fully, these solutions will bring wholeliver engineering a stage closer to being used in the clinic to address organ shortages.
Hepatocyte transplantation
Hepatocyte transplantation is an alterna tive to wholeorgan transplantation. Cells from a healthy donor are transplanted to a recipient with liver dysfunction. 4 The major problems with the cell transplantation approach are low rates of engraftment and poor survival of transplanted hepatocytes. 5 One approach to overcome this issue is to transplant hepatocytes that are contained in a carrier material, such as microcapsules (in which the cells are contained within a spherical membrane), 6 or within bio degradable scaffolds, 7 to provide a micro environment suitable for cell attachment and to protect the cells from the recipient's immune system. 8 Another reason for poor in vivo survival of transplanted hepatocytes is inadequate access to blood circulation for nutrient delivery and waste removal. Hepatocytes are highly metabolically active cells and without an adequate blood supply they rapidly die from a lack of oxygen and nutrients or exposure to the toxic products of metabolism. 9 Creating a liver-graft structure Traditional tissue engineering approaches for the development of liver grafts have been hampered by a lack of oxygen and nutrient diffusion, which limits the thick ness of the cell scaffolds to being sheetlike structures, usually engrafted in highly vas cularized regions. 10, 11 A hepatic mass that is sufficient to provide adequate metabolic function needs to contain a micro vascular network connected to the circulatory system to prevent the internal mass of the cells being subject to ischaemic damage. 12 A number of approaches to over coming this problem have been tested, such as attempting to mimic the native liver archi tecture using tissue engineering and micro fabrication techniques. These techniques can be used to fabricate micrometer scale channel networks on a solid substrate that resembles the tissue microvascular struc tures, such as the sinusoids and bile cana liculi in a hepatic lobule. These networks can then be seeded with hepatocytes, endothelial cells and cholangiocytes to establish an artificial perfusable, functional hepatic unit. Using this tissue engineering technology, an implantable, hepatocyte containing device could be created that can be connected to a recipient's circula tory system. 12, 13 Other approaches include the transplantation of cells or constructs into vascular tissue 7, 14 and use of scaf folds in tandem with angiogenic factors, such as vascular endothelial growth factor and basic fibroblast growth factor to stimulate rapid neovascularization of the implant. 15, 16 Only one study has demon strated any success in increasing survival rates in animal models of liver failure.
Whole-organ tissue engineering

Tissue decellularization
The first generation of tissue engineer ing materials used in scaffold fabrication, such as polylactic acid or polyglycolic acid, were of limited use as they lacked sufficient ability to modulate the repair and regen eration of the host tissue. 8 Consequently, interactions between materials and host tissues, such as control of specific cell binding interactions and response to environmental cues (for example, signals provided by soluble and insoluble growth factors, cytokines and extracellular matrix [ECM] molecules), 18 became impor tant considerations in the design of new mat erials. Wholeorgan decellulariza tion is an attractive scaffoldpreparation technique for tissue engineering as the resulting structure can potentially retain the architecture of the original tissue and functional components of the native micro vasculature, 19 as well as the native ECM composition, to a certain extent. 20 Potential applications of decellularized matrix in tissue engineering have already been demonstrated for a number of tissues, including bladder, 21 skin 22 and trachea. 23 The decellularized human skin Alloderm ® (LifeCell Corporation, New Jersey, USA), and small intestinal submucosa are among the most commercially successful examples of engineered tissue. 3 Decellularization of an entire heart through perfusion was first shown in 2008. 24 After the decellularization process the original ECM composition and its perfusable microvascular network were preserved. 24 Subsequent reports showed successful application of this technique to the liver [25] [26] [27] [28] [29] [30] and lung; [31] [32] [33] preliminary results for the kidney and pancreas have also been published. 34 Decellularized wholeliver scaffolds can be obtained from donor organs that are discarded because of damage and deemed unsuitable for transplantation. The approach for making wholeliver grafts is to repopulate the decellularized matrix scaffold with parenchymal and non parenchymal cells, ideally derived from pluripotent stem cells, and condi tioning the graft in vitro through perfusion with nutrients. The repopulated graft is hetero topically transplanted as an auxiliary support to a dysfunctional organ (Figure 1 ).
First recellularized rat livers
Our research group was the first to report the generation of a transplantable liver graft using a perfusiondecellularized liver matrix 25 and other reports followed. [26] [27] [28] [29] [30] The decellularization process preserved the structural and functional characteristics of the native microvascular network, which allowed subsequent recellularization with adult rat hepatocytes. 25 Recellularization efficiency with primary rat hepatocytes was high-over 90% of the hepatocytes infused into the portal vein remained in the scaf fold. 25 This efficiency figure indicates that the cells were retained within the graft, but does not necessarily indicate attach ment, engraftment or survival. In vitro perfusion culture of the recellularized liver graft showed that the graft supported liverspecific functions, including albumin secretion, urea synthesis and cytochrome P450 expression, at approximately 30% of the functional capacity of normal liver. Furthermore, after the recellularized liver grafts were transplanted in rats they sup ported hepatocyte survival and function with minimal ischaemic damage, albeit for a very short duration of 8 h. This report was followed by the creation of functional and viable transplantable rodent liver grafts using human foetal liver cells, 27, 29, 30 preparation of pig liver grafts using human foetal hepatocytes and stellate cells and very shortterm (2 h) transplant time. 30 Heterotopic transplantation of some recel lularized rat liver grafts survived up to 4 days. 26 However, the process of creating reengineered liver grafts involves several complicated procedures and there are still many hurdles to overcome.
Role of the extracellular matrix in liver
Changes in the expression of a variety of ECM components in the developing liver revealed by immunohistochemical analy sis provide strong evidence that ECM has a major role during hepatogenesis. 35 Maturation of sinusoidal vasculature, develop ment of hepatic architecture and hepatocyte growth and differentiation are some of the processes that are influenced by the ECM and several studies have success fully utilized natural ECM components to stabilize the adult hepatocyte pheno type 36, 37 and induce embryonic stem cells to differentiate into hepatocytelike cells. 38 Basement membrane proteins, such as laminin and fibronectin, as well as proteo glycans and their glycosaminoglycan side chains are directly involved in the integrin associated cellsignalling networks that determine cell responses to extracellular cues. 39 The importance of the ECM com ponents in modulating hepatocyte func tion and hepatic architecture highlights the advantage of using decellularized liver matrix as the scaffold material in successful liver engineering. However, few studies have directly evaluated the effect of the decellu larized liver matrix on stemcell fate 40, 41 and this effect remains an important direction for research. Preserving the extracellular matrix Liver ECM has a mixture of type I and type IV collagen, glycosaminoglycans, fibronectin, laminin and growth factors, as well as specialized spatial architecture of the sinusoids, forming the support for resident cells; all of these ECM factors have been shown to have a marked effect on cell behaviour, from attachment and differentia tion to function. 20 The ideal decellulariza tion technique would retain as much of this native composition and structure as pos sible, after removal of the cells. A compre hensive overview of the detergents and other methods that can be used for this purpose is beyond the scope of this article and has been reviewed elsewhere. 42 This article focuses on several insights gained from our research group's work on rat liver decellularization.
The liver is considered to have a limited ECM compared with connective tissue organs such as cartilage and bone, 43 but it has a surprisingly strong matrix that fully retains its original shape after decellulari zation-a decellularized liver does not feel very different from a nondecellularized liver when handled. The vessels are supple but robust and can be easily anastomosed with the recipient circulation. Although the vessels are able to withstand the pres sure of blood flow, as a precaution, it is best to avoid exposing the organ to full arterial flow pressure by adjusting the catheter size used in anastomosis.
Rapid decellularization with highly con centrated detergents leads to rapid release of cellular debris and increase of internal pressure, which is evident by ballooning of the organ, leading to the rupture of Glisson's capsule. As such, it is advisable to carry out the procedure slowly using a multistep procedure over about 4 days. 44 Correct posi tioning of the cannula for introducing the detergent is also critical to ensure the equal distribution of detergent over the entire organ, otherwise the peripheral tissue might not be adequately decellularized.
Detergents used to disrupt the cell mem brane and dissolve cytosolic material also dissolve many ECM components, such as growth factors and glycosaminoglycans. Several studies have indicated retention of the structural proteins in ratios similar to their normal composition; however, two reports on growth factors indicate that there are reductions in the level of growth factors such as HGF and EGF, to ~20% of the normal liver levels in a pig model 45 and ~50% in a rat model. 28 As the concentra tion and relative ratios of these factors can have considerable effects on cell behav iour, it might be necessary to reintroduce some of them to the decellularized graft. Studies to elucidate postdecellularization ECM changes in the context of cell attach ment, differentiation and maturation are urgently needed.
Rebuilding the liver
Choosing a cell source Choosing the source of cells is a complex qu e st i on w it h v ar i ou s c omp e t i ng approaches. There are several considera tions when deciding whether to use autolo gous or allogeneic cells (Box 1). Possible hepatocyte sources for human liver tissue engineering include primary human cells, cell lines, xenogeneic hepatocytes, and bipotent or pluripotent stem cells (including foetal hepatoblasts, embryonic stem cells and induced pluripotent stem cells). Induced pluripotent stem cells are the optimum cell type for the treatment of chronic liver diseases as they would be autologous cells and would reduce or remove the need for immune suppression. However, methods used to derive these stem cells are prone to problems such as retaining epigenetic memory, which could alter their potential to differentiate into cells of lineages other than those they were derived from. [46] [47] [48] The similarity of induced pluripotent stem cells to human embryonic stem cells has not been fully elucidated, but practical and scalable methods to dif ferentiate embryonic stem cells into mature hepatocytes that are equivalent to primary cells have not been established. 49 The cell source is not a major obstacle to tissue engineering but is an important consideration if preliminary clinical suc cesses are to be translated to commercial production scales. A potential cell source for initial studies is primary human hepato cytes recovered from cadaveric livers, which can be used to generate hepatocytes with equivalent or better viability and function compared with fresh hepatocytes in a rat model. 50 Foetal hepatoblasts are another ideal initial solution since they can be propagated easily in vitro, and readily dif ferentiate into hepatocytes and cholangio cytes. The ability of foetal hepatoblasts to differentiate into cholangiocytes could help to rebuild the biliary tree within the grafts. 51 Moreover, a promising study has already tested these cells for liver recel lularization and showed the formation of cyto keratin19positive ductules in the recellularized graft. 27 Recreating liver microarchitecture It is important to recreate the correct spatial distribution of parenchymal and non parenchymal cell types within the whole organ scaffold. Infusion of hepatocytes through the vasculature has been shown to be an efficient seeding technique for the distribution of cells into the parenchymal spaces of the scaffold compared with direct injection into the parenchyma. 25, 28 However, the infusion techniques used so far are the results of initial guesses and in our experi ence lead to highly uneven cell distribution within the tissue, as well as consider able variation between experiments. It is not diffi cult to direct hepatocytes into the parenchyma with continuous perfusion, 25, 28 but it is not known whether this is simply because the vascular bed is very porous after cells are removed and because of the flow pressure during perfusion culture, or if there is a migration and homing factor involved; for practical purposes this is not an important question. However, lack of even distribution is a practical problem that creates a barrier to consistency in the manufacture of recellularized grafts.
Multistep dynamic seeding of hepato cytes results in their uniform distribution. 25 If nonparenchymal cells are introduced into the scaffolds, endothelial cells and hepato cytes seem to attach to their respec tive niches more readily than if the non parenchymal cells are not introduced. 25, 27 Infusion through different circulatory systems, the portal and venous routes 27 or sequential seeding of different cell types (hepatocytes followed by endothelial cells) 25 can be used to restrict the distribution of the endothelial cells into the vascular spaces and hepatocytes into the parenchyma. Repopulation of the biliary tree with chol angiocytes has not been reported but it is thought that the cells would be physically contained in the biliary channels that are preserved in the wholeliver scaffolds 28 if they are infused into the bile ducts. In addition, it has been suggested that ECM matrix components have zonal variation in the decellularized scaffold; 40 therefore, it is likely that the biliary channel ECM would contain signals that favour the engraftment of cholangiocytes at the site.
Box 1 | Autologous and allogeneic cells
When hepatocyte density is limited to ~20% of that in normal liver tissue, histo logical investigations indicate a mixture of zones. 25 The first zone consists of tissue that is similar to healthy liver. The second zone has high concentrations of dead cells (typically within the vascular bed), probably because of occlusion and consequent necro sis owing to inadequate perfusion. The third zone is very sparsely populated with cells that are mostly dead, most likely as a result of apoptosis caused by the absence of cell-cell contact. Cell density should be increased to create confluent hepatic mass within the parenchyma although, from experience with in vitro culture of primary hepatocytes and recellularized grafts, it is clear that there is an optimum range of seeding density. If there are too few cells, insufficient cell-cell attachment and inter actions leads to formation of sparse colonies rather than a liverlike confluent hepatocyte mass. However, seeding too many cells leads to a large number of dead cells, adversely affecting the culture viability, probably owing to the cell debris causing immune or apoptotic signalling events in the other wise healthy hepatocytes. Overseeding is a particular problem in decellularized wholeliver grafts as excessive numbers of cells can create occlusion in the vessels and massive cell death. Our own experi ences indicate that ~80% of the cell density found in normal liver tissues could be effec tive, although optimization of the seeding process is needed. Multistep seeding could prevent the increased density creating even more occlusion zones. 28 Studies are urgently needed to explore this technical aspect.
Generally, obtaining human endo thelial cells is not problematic because most endothelial cell subtypes can be expanded in vitro. However, liver sinusoidal endo thelial cells are difficult to obtain and main tain, and two reports on endothelialization of liver scaffolds have used other types of endothelial cells, such as rat cardiac micro vascular endothelial cells 25 and human umbilical cord vascular endothelial cells. 27 In our opinion, this is a satisfactory short term solution. Hepatocytes and chol angiocytes, however, do not expand well in vitro and can be problematic when used for recellularization.
Preventing graft rejection
Liver origin and immune rejection Sourcing livers for decellularization is, surprisingly, not an immediate problem. One option is pig livers, which are easy to obtain and ensure quality. However, use of xenogeneic tissues could lead to hyperacute transplant rejection because of recipient antibodies against galactoseα1,3galactose (the αgal epitope), which is expressed by pig tissue. 52 However, after decellulariza tion, xenogeneic tissue does not seem to generate an adverse immune response, but a constructive remodelling response was shown in an African Green monkey abdom inal wall resection model. 53 Although there was an initial increase in serum αgal anti bodies with normal xenogeneic grafts when compared with xenogeneic grafts obtained from αgaldeficient pigs, the serum anti body levels reached normal levels 90 days after transplantation. 53 Furthermore, an αgalknockout pig has been engineered and implantation of decellularized dermal matrix from knockout pigs in a nonhuman primate model resulted in a minimal or no response to αgal. 54 Human donor organs are often unused and are available for decellularization. Livers are rejected for transplant because of excessive steatosis, fibrosis and cirrhosis, or levels of ischaemia that are beyond accept able limits. It is estimated that the number of mildly ischaemic livers is in the order of 6,000 per year 55 and these livers could potentially be recovered for transplantation by machine perfusion; 56 therefore, many more thousands of livers are accessible for human liver decellularization. Importantly, some of the pathologies that lead to rejec tion for transplant could have effects on the quality of ECM and it is not yet clear if this damage will impair recellularization. In our opinion, human livers will be the preferred source of organs for clinical trials of decellularization techniques; however, if this process is used for commercial scale production, pig livers could be preferable in order to reduce costs and for ease of standardization and quality assurance.
Preventing coagulation
Prevention of blood coagulation is diffi cult to achieve and failure to do so hinders longterm in vivo testing of the recellular ized liver grafts. Blood contact is normally restricted to the endothelium and the coagulation cascade is initiated if blood is exposed to tissue collagen underlying the damaged endothelium at an injury site, through direct and indirect interactions of collagen with platelet glycoprotein surface receptors. 57 Unless the graft has been fully recellularized to conceal collagen, coagula tion will occur when the graft is exposed to circulating blood. Coagulation can be prevented in vivo by covering the vascular bed in the decellularized matrix scaffold with endothelial cells. 24, 25, 27, 31 In practice, achieving nearperfect endothelial cell coverage of the vasculature in the scaffold is challenging. Administration of systemic anti coagulants has been used in experimen tal models for heterotopic transplantation of the recellularized liver grafts; however, although successful in preventing thrombo sis, this led to complications such as haem orrhage and the recipients did not survive beyond 8 h. For similar reasons, most attempts at transplantation of the whole liver scaffolds have been limited to only a few hours. [25] [26] [27] 30 A promising solution is to deposit heparin layers on the decellularized matrix scaffold and render the wholeliver graft blood compatible. 26 Recipients of hep arinized and recellularized grafts survived for up to 96 h compared with rats that had received recellularized grafts without heparin, which only survived for 16 h after 90% hepatectomy. 26 Although hepariniza tion of the grafts is a major improvement, the efficacy and safety of this technique still needs to be tested.
Transplantation of recellularized grafts
Ideally, a recellularized graft would be equivalent to a native liver, featuring the hepatic artery, vena cava, portal vein and the bile duct, and could be orthotopically transplanted to the recipient to replace their dysfunctional liver. Heterotopic transplan tation might be more practical, particularly for early in vivo investigations, as it would not be necessary for the recellularized graft to fully substitute for the liver. As such, heterotypic transplantation has been the preferred approach in the in vivo studies performed so far.
In a rat model study by our research group, 25 left nephrectomy was carried out to provide an arterial blood supply for the graft, which was connected to the portal vein and the renal vein to draw blood via suprahepatic vena cava. A heparinized cath eter was used for anastomosing the vessels. This approach also enabled the pressure of the arterial blood being delivered into the graft to be reduced by using slightly nar rower catheters, which was necessary as the pressure could cause leakage through the capsule of the graft. The leakage was prob ably because the graft was not fully recel lularized. Although nephrectomy is feasible in animal models to create space as well as vascular connection points it is a clinically unlikely scenario.
An alternative approach is to transplant the graft into the intraabdominal cavity in a serial configuration with the recipient liver without removal of any organs or tissues. 27 In the study that used this approach, the recipient superior mesenteric vein and vena cave were anastomosed to the graft portal vein and vena cava respectively; however, the graft survived for 60 min in vivo before clotting occurred. 27 In a different approach, the native liver has been hepatectomized, the recellular ized graft transplanted in series and the graft portal vein and the superior hepatic vena cava anastomosed to the recipient's inferior and superior portal vein using the cuff method. 59, 60 In one study that took this approach the recipients lived up to 4 days. 26 Low blood flow and high resistance were observed within the graft, as well as small forsize syndrome, which consists of portal hypertension, gastrointestinal congestion and ascites. However, the recipient had 90% hepatectomy and without the graft, survival was <2 days. Furthermore, the grafts were heparin coated to prevent or reduce blood coagulation, making comparisons difficult with other works. Ectopic, serial approaches are generally complicated surgical proce dures, particularly in small animal models like the rat; however, they could be viable in humans, particularly when only a section of the liver (such as the smaller right lobe) is transplanted.
Another approach we have used com bines nephrectomy and serial approaches. Right nephrectomy was performed to create space for the graft and the renal artery was tiedoff. The graft was transplanted in series with the intrahepatic vena cava using the cuff method. Coagulation reduced post transplant compared with our previous approach because of the cuff method, and decellularized graft recipients survived up to 4 weeks without heparinization. Although the periphery contained coagulated blood, the main flow sections appeared histologi cally normal, and would probably be able to support viable hepatocytes (K. Uygun, unpublished data). Extending recipient survival to a month means that factors such as cell survival and matrix remodelling can be studied in extensive detail, which was not possible previously.
Several technical and conceptual ques tions are yet to be resolved. The graft can be transplanted without removing any abdom inal organs, particularly if a single lobe is used. Highpressure arterial blood flow risks causing damage to the graft, although it provides highly oxygenated, pulsatile flow. By contrast, the venous flow is less likely to cause pressurerelated damage and is easier to manage surgically, but it contains less oxygen and laminar flow. In the liver, arte rial flow primarily feeds the biliary tree and ~90% of the blood supply in the rat liver comes from the portal vein. 61 Therefore, the absence of an arterial blood connection to the graft might not prove critical for hepato cyte survival. It is not known whether pul satile flow characteristics, vessel pressure or graft location will have a major effect on cell survival within the graft, and further research into these factors is required.
Moving towards clinical trials
Each step of the wholeliver engineer ing process discussed above presents a set of challenges that need to be addressed; however, it is encouraging that for each step there is, at least, some preliminary success in small animal models. Therefore, the main challenges revolve around scalingup to clinically applicable graft dimensions and achieving in vivo viability and function in order to progress to clinical trials.
Although decellularized wholeliver grafts are promising as a breakthrough for vascular tissues, major challenges need to be overcome. First and foremost is achiev ing adequate capillary structure and, there fore, longterm in vivo viability. Although perfusiondecellularized grafts retain an intact circulatory system at a clinically rele vant scale, the decellularization process still destroys the capillary structures, which are composed of endothelial cells. The limita tion of oxygen diffusion beyond ~200 μm means that a capillarytype structure needs to be reconstituted within the graft to keep the hepatocytes alive after transplantation. Therefore, the first goal is to create capil lary structures with endothelial cells in the decellularized liver grafts.
The second major challenge to address is to ensure that there is a functioning biliary system, which might require the entire sinusoidal microarchitecture to be formed. It has been demonstrated that the biliary tree architecture in the liver is preserved after decellularization, 45 and retrograde infusion of cholangiocytes through the bile duct could be a way to seed these cells with proper spatial distribution. In order to create fully functional liver grafts, it is necessary to either induce the cells to reform the biliary tree, preferably in vitro but it could possibly be done in vivo during remodelling, as com ponents of bile are toxic for hepatocytes. For temporary, auxiliary grafts used to provide shortterm liver support, some degree of hyper bilirubinaemia might be tolerated without inducing major harm to the patient or the graft, as bilirubin toxicity is more of a chronic problem. Mildly elevated bilirubin is welltolerated and in more severe cases such as CriglerNajjar syndrome, mainte nance therapies, for example phototherapy, can be used for shortterm management while the patient is awaiting a donor liver for transplantation. 62, 63 Successfully treating acute liver failure with tissueengineered liver grafts would justify the research into this technique, enabling treatment of 1,600 more patients with acute liver failure per year in the USA alone, 64, 65 and some of the livers that are cur rently transplanted into patients with acute liver failure could be used to treat patients with chronic liver failure. The regenerative properties of the liver mean that it is the only organ with a large error margin for creating tissueengineered replacements. Therefore, in our opinion, the liver (particularly in an acute failure setting) is an excellent step ping stone in the creation of complete laboratorygrown organ substitutes.
Conclusions
Wholeorgan tissue engineering is complex and involves many technically challenging steps that need to be performed successfully in series. As such, it is possible that even if individual issues are addressed, the result ing protocol will be so prone to failure that it will only ever have a few limited successes. However, these difficulties are counter balanced by the fact that wholeorgan tissue engineering is a unique platform that allows integration of the fields of biomaterials, ECM and developmental biology, biomedical device engineering and transplant surgery, creating a truly multidisciplinary field with an emphasis on translational success.
